PDS Biotechnology (PDSB) Change in Accured Expenses (2014 - 2025)

PDS Biotechnology (PDSB) has 12 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q4 2025.

• Quarterly Change in Accured Expenses rose 18.21% year-over-year to -$1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.1 million (down 603.93% YoY) and the FY2025 annual result came in at -$2.1 million, down 603.93% from the prior year.
• Change in Accured Expenses slipped to -$1.3 million in Q4 2025, from $622306.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.9 million in Q4 2022 to a low of -$6.5 million in Q1 2023.
• A 5-year average of -$49654.8 and a median of $122527.5 in 2021 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2130.44% — and 2023, when it plunged 2753.36%.
• Tracing PDSB's Change in Accured Expenses over 5 years: stood at $263858.0 in 2021, then surged by 2130.44% to $5.9 million in 2022, then slumped by 122.23% to -$1.3 million in 2023, then decreased by 25.25% to -$1.6 million in 2024, then rose by 18.21% to -$1.3 million in 2025.
• The last three Change in Accured Expenses figures came in at -$1.3 million (Q4 2025), $622306.0 (Q3 2025), and -$1.3 million (Q2 2025), per Business Quant data.